Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

By  

CANCER, Vol. 121, Iss. 23, 2015-12 ,pp. : 4158-4164

John Wiley & Sons Inc

Access to resources Recommend Favorite

All‐trans retinoic acid and arsenic combination therapy benefits low‐to‐intermediate‐risk patients with newly diagnosed acute promyelocytic leukaemia: a long‐term follow‐up based on multivariate analysis

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 2, 2015-10 ,pp. : 277-280

John Wiley & Sons Inc

Access to resources Recommend Favorite

All‐trans retinoic acid and arsenic combination therapy benefits low‐to‐intermediate‐risk patients with newly diagnosed acute promyelocytic leukaemia: a long‐term follow‐up based on multivariate analysis

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 7-1048, Iss. 2, 2015-10 ,pp. : 277-280

John Wiley & Sons Inc

Access to resources Recommend Favorite

Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 1002-1009

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome‐positive acute lymphoblastic leukemia

By  

CANCER, Vol. 120, Iss. 10, 2014-05 ,pp. : 1514-1519

John Wiley & Sons Inc

Access to resources Recommend Favorite